Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease
Introduction Medullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer. Familial cases of MTC are associated with RET mutations whilst RAS mutations appear to be a frequent finding in RET negative tumours. The aims of t...
Uložené v:
| Vydané v: | World journal of surgery Ročník 42; číslo 5; s. 1432 - 1439 |
|---|---|
| Hlavní autori: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Cham
Springer International Publishing
01.05.2018
John Wiley & Sons, Inc |
| Predmet: | |
| ISSN: | 0364-2313, 1432-2323, 1432-2323 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Introduction
Medullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer. Familial cases of MTC are associated with RET mutations whilst
RAS
mutations appear to be a frequent finding in RET negative tumours. The aims of this study were to analyse survival outcomes in MTC and to evaluate the role of
RAS
immunohistochemistry in the identification of sporadic disease.
Materials and methods
A retrospective cohort study of consecutive patients with MTC was undertaken. The primary outcome measures were overall survival and disease-free survival. Survival analysis was performed on the basis of sporadic and familial disease. Patients had routine RET testing using the capillary (Sanger) sequencing method. Histopathological MTC slides from 100 patients were tested for HRASQ61R, a common somatic
RAS
mutation in MTC, with mutation-specific immunohistochemistry (IHC).
Results
A total of 195 patients had surgical treatment of MTC in the period 1980 to 2016. There were 83 males and 112 females with a mean age of 53.0 years. A total of 39 (20%) patients had familial disease. Sporadic cases had a higher median pre-op calcitonin (969.5 vs. 257.5 pg/ml), greater mean primary tumour size (23.5 vs. 12.5 mm) and more distant metastases (12.8 vs. 10.3%). Multivariate analysis showed age (
p
= 0.005), Multiple Endocrine Neoplasia Type 2 (MEN2) status (
p
= 0.021) and distant metastasis (
p
= 0.002) to be significant independent predictors of survival. Significant independent predictors for disease-free survival were age (
p
= 0.015), MEN2 (
p
= 0.002), pre-op calcitonin (
p
= 0.033) and venous invasion (
p
= 0.001). The overall 5-year survival was 100% for familial MTC and 78% for sporadic MTC. The 10-year disease-free survival was 94% for familial MTC and 61% for sporadic cases. A total of 100 cases of MTC underwent mutation-specific IHC for HRASQ61R. Of these, 18 had confirmed MEN2. IHC had 100% specificity in excluding MEN2. Twelve (12%) of 100 patients stained positive for HRASQ61R mutation.
Conclusion
In the era of genetic testing, RET status significantly influences disease-specific survival in MTC. Mutation-specific IHC for HRASQ61R may have a role in the identification of patients presenting with sporadic disease. |
|---|---|
| AbstractList | Introduction
Medullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer. Familial cases of MTC are associated with RET mutations whilst RAS mutations appear to be a frequent finding in RET negative tumours. The aims of this study were to analyse survival outcomes in MTC and to evaluate the role of RAS immunohistochemistry in the identification of sporadic disease.
Materials and methods
A retrospective cohort study of consecutive patients with MTC was undertaken. The primary outcome measures were overall survival and disease‐free survival. Survival analysis was performed on the basis of sporadic and familial disease. Patients had routine RET testing using the capillary (Sanger) sequencing method. Histopathological MTC slides from 100 patients were tested for HRASQ61R, a common somatic RAS mutation in MTC, with mutation‐specific immunohistochemistry (IHC).
Results
A total of 195 patients had surgical treatment of MTC in the period 1980 to 2016. There were 83 males and 112 females with a mean age of 53.0 years. A total of 39 (20%) patients had familial disease. Sporadic cases had a higher median pre‐op calcitonin (969.5 vs. 257.5 pg/ml), greater mean primary tumour size (23.5 vs. 12.5 mm) and more distant metastases (12.8 vs. 10.3%). Multivariate analysis showed age (p = 0.005), Multiple Endocrine Neoplasia Type 2 (MEN2) status (p = 0.021) and distant metastasis (p = 0.002) to be significant independent predictors of survival. Significant independent predictors for disease‐free survival were age (p = 0.015), MEN2 (p = 0.002), pre‐op calcitonin (p = 0.033) and venous invasion (p = 0.001). The overall 5‐year survival was 100% for familial MTC and 78% for sporadic MTC. The 10‐year disease‐free survival was 94% for familial MTC and 61% for sporadic cases. A total of 100 cases of MTC underwent mutation‐specific IHC for HRASQ61R. Of these, 18 had confirmed MEN2. IHC had 100% specificity in excluding MEN2. Twelve (12%) of 100 patients stained positive for HRASQ61R mutation.
Conclusion
In the era of genetic testing, RET status significantly influences disease‐specific survival in MTC. Mutation‐specific IHC for HRASQ61R may have a role in the identification of patients presenting with sporadic disease. Introduction Medullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer. Familial cases of MTC are associated with RET mutations whilst RAS mutations appear to be a frequent finding in RET negative tumours. The aims of this study were to analyse survival outcomes in MTC and to evaluate the role of RAS immunohistochemistry in the identification of sporadic disease. Materials and methods A retrospective cohort study of consecutive patients with MTC was undertaken. The primary outcome measures were overall survival and disease-free survival. Survival analysis was performed on the basis of sporadic and familial disease. Patients had routine RET testing using the capillary (Sanger) sequencing method. Histopathological MTC slides from 100 patients were tested for HRASQ61R, a common somatic RAS mutation in MTC, with mutation-specific immunohistochemistry (IHC). Results A total of 195 patients had surgical treatment of MTC in the period 1980 to 2016. There were 83 males and 112 females with a mean age of 53.0 years. A total of 39 (20%) patients had familial disease. Sporadic cases had a higher median pre-op calcitonin (969.5 vs. 257.5 pg/ml), greater mean primary tumour size (23.5 vs. 12.5 mm) and more distant metastases (12.8 vs. 10.3%). Multivariate analysis showed age ( p = 0.005), Multiple Endocrine Neoplasia Type 2 (MEN2) status ( p = 0.021) and distant metastasis ( p = 0.002) to be significant independent predictors of survival. Significant independent predictors for disease-free survival were age ( p = 0.015), MEN2 ( p = 0.002), pre-op calcitonin ( p = 0.033) and venous invasion ( p = 0.001). The overall 5-year survival was 100% for familial MTC and 78% for sporadic MTC. The 10-year disease-free survival was 94% for familial MTC and 61% for sporadic cases. A total of 100 cases of MTC underwent mutation-specific IHC for HRASQ61R. Of these, 18 had confirmed MEN2. IHC had 100% specificity in excluding MEN2. Twelve (12%) of 100 patients stained positive for HRASQ61R mutation. Conclusion In the era of genetic testing, RET status significantly influences disease-specific survival in MTC. Mutation-specific IHC for HRASQ61R may have a role in the identification of patients presenting with sporadic disease. Medullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer. Familial cases of MTC are associated with RET mutations whilst RAS mutations appear to be a frequent finding in RET negative tumours. The aims of this study were to analyse survival outcomes in MTC and to evaluate the role of RAS immunohistochemistry in the identification of sporadic disease. A retrospective cohort study of consecutive patients with MTC was undertaken. The primary outcome measures were overall survival and disease-free survival. Survival analysis was performed on the basis of sporadic and familial disease. Patients had routine RET testing using the capillary (Sanger) sequencing method. Histopathological MTC slides from 100 patients were tested for HRASQ61R, a common somatic RAS mutation in MTC, with mutation-specific immunohistochemistry (IHC). A total of 195 patients had surgical treatment of MTC in the period 1980 to 2016. There were 83 males and 112 females with a mean age of 53.0 years. A total of 39 (20%) patients had familial disease. Sporadic cases had a higher median pre-op calcitonin (969.5 vs. 257.5 pg/ml), greater mean primary tumour size (23.5 vs. 12.5 mm) and more distant metastases (12.8 vs. 10.3%). Multivariate analysis showed age (p = 0.005), Multiple Endocrine Neoplasia Type 2 (MEN2) status (p = 0.021) and distant metastasis (p = 0.002) to be significant independent predictors of survival. Significant independent predictors for disease-free survival were age (p = 0.015), MEN2 (p = 0.002), pre-op calcitonin (p = 0.033) and venous invasion (p = 0.001). The overall 5-year survival was 100% for familial MTC and 78% for sporadic MTC. The 10-year disease-free survival was 94% for familial MTC and 61% for sporadic cases. A total of 100 cases of MTC underwent mutation-specific IHC for HRASQ61R. Of these, 18 had confirmed MEN2. IHC had 100% specificity in excluding MEN2. Twelve (12%) of 100 patients stained positive for HRASQ61R mutation. In the era of genetic testing, RET status significantly influences disease-specific survival in MTC. Mutation-specific IHC for HRASQ61R may have a role in the identification of patients presenting with sporadic disease. IntroductionMedullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer. Familial cases of MTC are associated with RET mutations whilst RAS mutations appear to be a frequent finding in RET negative tumours. The aims of this study were to analyse survival outcomes in MTC and to evaluate the role of RAS immunohistochemistry in the identification of sporadic disease.Materials and methodsA retrospective cohort study of consecutive patients with MTC was undertaken. The primary outcome measures were overall survival and disease-free survival. Survival analysis was performed on the basis of sporadic and familial disease. Patients had routine RET testing using the capillary (Sanger) sequencing method. Histopathological MTC slides from 100 patients were tested for HRASQ61R, a common somatic RAS mutation in MTC, with mutation-specific immunohistochemistry (IHC).ResultsA total of 195 patients had surgical treatment of MTC in the period 1980 to 2016. There were 83 males and 112 females with a mean age of 53.0 years. A total of 39 (20%) patients had familial disease. Sporadic cases had a higher median pre-op calcitonin (969.5 vs. 257.5 pg/ml), greater mean primary tumour size (23.5 vs. 12.5 mm) and more distant metastases (12.8 vs. 10.3%). Multivariate analysis showed age (p = 0.005), Multiple Endocrine Neoplasia Type 2 (MEN2) status (p = 0.021) and distant metastasis (p = 0.002) to be significant independent predictors of survival. Significant independent predictors for disease-free survival were age (p = 0.015), MEN2 (p = 0.002), pre-op calcitonin (p = 0.033) and venous invasion (p = 0.001). The overall 5-year survival was 100% for familial MTC and 78% for sporadic MTC. The 10-year disease-free survival was 94% for familial MTC and 61% for sporadic cases. A total of 100 cases of MTC underwent mutation-specific IHC for HRASQ61R. Of these, 18 had confirmed MEN2. IHC had 100% specificity in excluding MEN2. Twelve (12%) of 100 patients stained positive for HRASQ61R mutation.ConclusionIn the era of genetic testing, RET status significantly influences disease-specific survival in MTC. Mutation-specific IHC for HRASQ61R may have a role in the identification of patients presenting with sporadic disease. Medullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer. Familial cases of MTC are associated with RET mutations whilst RAS mutations appear to be a frequent finding in RET negative tumours. The aims of this study were to analyse survival outcomes in MTC and to evaluate the role of RAS immunohistochemistry in the identification of sporadic disease.INTRODUCTIONMedullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer. Familial cases of MTC are associated with RET mutations whilst RAS mutations appear to be a frequent finding in RET negative tumours. The aims of this study were to analyse survival outcomes in MTC and to evaluate the role of RAS immunohistochemistry in the identification of sporadic disease.A retrospective cohort study of consecutive patients with MTC was undertaken. The primary outcome measures were overall survival and disease-free survival. Survival analysis was performed on the basis of sporadic and familial disease. Patients had routine RET testing using the capillary (Sanger) sequencing method. Histopathological MTC slides from 100 patients were tested for HRASQ61R, a common somatic RAS mutation in MTC, with mutation-specific immunohistochemistry (IHC).MATERIALS AND METHODSA retrospective cohort study of consecutive patients with MTC was undertaken. The primary outcome measures were overall survival and disease-free survival. Survival analysis was performed on the basis of sporadic and familial disease. Patients had routine RET testing using the capillary (Sanger) sequencing method. Histopathological MTC slides from 100 patients were tested for HRASQ61R, a common somatic RAS mutation in MTC, with mutation-specific immunohistochemistry (IHC).A total of 195 patients had surgical treatment of MTC in the period 1980 to 2016. There were 83 males and 112 females with a mean age of 53.0 years. A total of 39 (20%) patients had familial disease. Sporadic cases had a higher median pre-op calcitonin (969.5 vs. 257.5 pg/ml), greater mean primary tumour size (23.5 vs. 12.5 mm) and more distant metastases (12.8 vs. 10.3%). Multivariate analysis showed age (p = 0.005), Multiple Endocrine Neoplasia Type 2 (MEN2) status (p = 0.021) and distant metastasis (p = 0.002) to be significant independent predictors of survival. Significant independent predictors for disease-free survival were age (p = 0.015), MEN2 (p = 0.002), pre-op calcitonin (p = 0.033) and venous invasion (p = 0.001). The overall 5-year survival was 100% for familial MTC and 78% for sporadic MTC. The 10-year disease-free survival was 94% for familial MTC and 61% for sporadic cases. A total of 100 cases of MTC underwent mutation-specific IHC for HRASQ61R. Of these, 18 had confirmed MEN2. IHC had 100% specificity in excluding MEN2. Twelve (12%) of 100 patients stained positive for HRASQ61R mutation.RESULTSA total of 195 patients had surgical treatment of MTC in the period 1980 to 2016. There were 83 males and 112 females with a mean age of 53.0 years. A total of 39 (20%) patients had familial disease. Sporadic cases had a higher median pre-op calcitonin (969.5 vs. 257.5 pg/ml), greater mean primary tumour size (23.5 vs. 12.5 mm) and more distant metastases (12.8 vs. 10.3%). Multivariate analysis showed age (p = 0.005), Multiple Endocrine Neoplasia Type 2 (MEN2) status (p = 0.021) and distant metastasis (p = 0.002) to be significant independent predictors of survival. Significant independent predictors for disease-free survival were age (p = 0.015), MEN2 (p = 0.002), pre-op calcitonin (p = 0.033) and venous invasion (p = 0.001). The overall 5-year survival was 100% for familial MTC and 78% for sporadic MTC. The 10-year disease-free survival was 94% for familial MTC and 61% for sporadic cases. A total of 100 cases of MTC underwent mutation-specific IHC for HRASQ61R. Of these, 18 had confirmed MEN2. IHC had 100% specificity in excluding MEN2. Twelve (12%) of 100 patients stained positive for HRASQ61R mutation.In the era of genetic testing, RET status significantly influences disease-specific survival in MTC. Mutation-specific IHC for HRASQ61R may have a role in the identification of patients presenting with sporadic disease.CONCLUSIONIn the era of genetic testing, RET status significantly influences disease-specific survival in MTC. Mutation-specific IHC for HRASQ61R may have a role in the identification of patients presenting with sporadic disease. |
| Author | Gill, A. J. Robinson, B. Clifton-Bligh, R. Sywak, M. Reagh, J. Learoyd, D. Bullock, M. Aniss, A. Delbridge, L. Sidhu, S. Jayakody, S. |
| Author_xml | – sequence: 1 givenname: S. surname: Jayakody fullname: Jayakody, S. organization: University of Sydney Endocrine Surgical Unit – sequence: 2 givenname: J. surname: Reagh fullname: Reagh, J. organization: Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney – sequence: 3 givenname: M. surname: Bullock fullname: Bullock, M. organization: Department of Endocrinology, Royal North Shore Hospital – sequence: 4 givenname: A. surname: Aniss fullname: Aniss, A. organization: University of Sydney Endocrine Surgical Unit – sequence: 5 givenname: R. surname: Clifton-Bligh fullname: Clifton-Bligh, R. organization: Department of Endocrinology, Royal North Shore Hospital – sequence: 6 givenname: D. surname: Learoyd fullname: Learoyd, D. organization: Department of Endocrinology, Royal North Shore Hospital – sequence: 7 givenname: B. surname: Robinson fullname: Robinson, B. organization: Department of Endocrinology, Royal North Shore Hospital – sequence: 8 givenname: L. surname: Delbridge fullname: Delbridge, L. organization: University of Sydney Endocrine Surgical Unit – sequence: 9 givenname: S. surname: Sidhu fullname: Sidhu, S. organization: University of Sydney Endocrine Surgical Unit – sequence: 10 givenname: A. J. surname: Gill fullname: Gill, A. J. organization: Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney – sequence: 11 givenname: M. surname: Sywak fullname: Sywak, M. email: marksywak@nebsc.com.au organization: University of Sydney Endocrine Surgical Unit |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29484475$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkctu1DAUhi1URKeFB2CDLLHpJmA78SXsyrSFVq1YTBFLy3FOGFeJPdhJq3kDHhsPaUGqVPDmHFnffy7_OUB7PnhA6DUl7ygh8n0ihAlVEKqKinNaqGdoQauSFaxk5R5akFJUOaflPjpI6YYQKgURL9A-qytVVZIv0M8raKe-N3GLr9fbGFyLlyZa58NgPuDVFG_drenxsTf9NrmEjW_xaf6ZzOiCx6HDV9P4Oy9WG7CucxafD8Pkw9qlMdg1DDnm6s7jExjBPshWmxBNm-kTl8AkeImed6ZP8Oo-HqKvZ6fXy8_F5ZdP58vjy8JWjMnCWkF5Hl6CgZYAkU1jeGNbVXXAKedCEmiYaoy0oqyFFaarO1E1jDLeGVGWh-horruJ4ccEadR5QAvZAg9hSpoRovKrOcno20foTZhidmKmaC0ZlZl6c09NzQCt3kQ3ZDv1g8cZoDNgY0gpQvcHoUTv7qjnO-p8R727o1ZZIx9prJttHqNx_T-V9ay8cz1s_99Kf7tYfTwjSvLdKmzWpizz3yH-Xfjphr8AUq3Dzw |
| CitedBy_id | crossref_primary_10_3390_cancers12113124 crossref_primary_10_3390_diseases6020025 crossref_primary_10_1016_j_surg_2020_03_009 crossref_primary_10_1080_07435800_2024_2344103 crossref_primary_10_1016_j_amjoto_2024_104570 crossref_primary_10_1210_clinem_dgab326 crossref_primary_10_1007_s12020_022_03296_1 crossref_primary_10_1007_s12022_024_09839_8 crossref_primary_10_1038_s41417_023_00691_2 crossref_primary_10_1530_EJE_18_1008 |
| Cites_doi | 10.1002/cncr.28661 10.1097/PAI.0000000000000333 10.1210/jc.2012-2092 10.1210/jc.2005-1278 10.1089/thy.2008.0403 10.1111/j.1365-2265.2004.02037.x 10.1001/jama.1996.03540190047028 10.1016/j.endonu.2014.02.006 10.1089/thy.2014.0335 10.1210/jc.2013-1204 10.1530/ERC-15-0070 10.1158/1078-0432.CCR-08-2742 10.1111/cas.12959 10.1001/archsurg.1997.01430330088015 10.2174/138920211798120835 10.1007/978-3-319-29998-3_3 10.1210/jc.2010-1921 10.1097/PAS.0000000000000740 10.1177/1947601911411084 10.1111/j.1365‐2265.2004.02037.x 10.1210/jc.2012‐2092 10.1007/978‐3‐319‐29998‐3_3 10.1210/jc.2013‐1204 10.1210/jc.2005‐1278 10.1210/jc.2010‐1921 10.1158/1078‐0432.CCR‐08‐2742 10.1530/ERC‐15‐0070 |
| ContentType | Journal Article |
| Copyright | Société Internationale de Chirurgie 2018 2018 The Author(s) under exclusive licence to Société Internationale de Chirurgie World Journal of Surgery is a copyright of Springer, (2018). All Rights Reserved. |
| Copyright_xml | – notice: Société Internationale de Chirurgie 2018 – notice: 2018 The Author(s) under exclusive licence to Société Internationale de Chirurgie – notice: World Journal of Surgery is a copyright of Springer, (2018). All Rights Reserved. |
| DBID | AAYXX CITATION NPM 3V. 7QO 7T5 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FR3 FYUFA GHDGH H94 K9. M0S M1P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s00268-018-4551-8 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Biotechnology Research Abstracts Immunology Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Database Suite (ProQuest) ProQuest One Community College Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biotechnology and BioEngineering Abstracts Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed Technology Research Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central Database Suite (ProQuest) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1432-2323 |
| EndPage | 1439 |
| ExternalDocumentID | 29484475 10_1007_s00268_018_4551_8 WJSBF08757 |
| Genre | article Journal Article |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 123 199 1N0 1OC 1SB 2.D 203 28- 29R 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAHQN AAIAL AAIPD AAJBT AAJKR AAMNL AANXM AANZL AAQQT AARHV AARTL AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMOR ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABQWH ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBXY ACGFS ACHSB ACHVE ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADIYS ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFFPM AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGWIL AGWZB AGYKE AHAVH AHBTC AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AITYG AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DCZOG DDRTE DL5 DNIVK DPUIP DU5 EBD EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HGLYW HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z J5H JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- MEWTI N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SUPJJ SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 WXSBR X7M YLTOR Z45 Z7U Z7X Z82 Z83 Z87 Z8O Z8V Z8W Z91 Z92 ZGI ZMTXR ZOVNA ~EX AAMMB AAYXX ABFSG ACSTC ADHKG AEFGJ AEYWJ AEZWR AFFHD AFHIU AGHNM AGQPQ AGXDD AGYGG AHPBZ AHWEU AIDQK AIDYY AIXLP ATHPR AYFIA CITATION EBLON LH4 PHGZM PHGZT PJZUB PPXIY NPM 7QO 7T5 7XB 8FD 8FK FR3 H94 K9. P64 PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c4227-cc6154847eaed0e07bba5bcd84fe5155670eb28ba7c6396c6af9f64b2125fa633 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 12 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000429808200029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0364-2313 1432-2323 |
| IngestDate | Sat Sep 27 19:25:46 EDT 2025 Tue Oct 07 05:55:08 EDT 2025 Wed Feb 19 02:43:48 EST 2025 Tue Nov 18 21:22:17 EST 2025 Sat Nov 29 01:51:55 EST 2025 Wed Jan 22 16:19:03 EST 2025 Fri Feb 21 02:31:54 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4227-cc6154847eaed0e07bba5bcd84fe5155670eb28ba7c6396c6af9f64b2125fa633 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 29484475 |
| PQID | 2008197217 |
| PQPubID | 47185 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2008888950 proquest_journals_2008197217 pubmed_primary_29484475 crossref_primary_10_1007_s00268_018_4551_8 crossref_citationtrail_10_1007_s00268_018_4551_8 wiley_primary_10_1007_s00268_018_4551_8_WJSBF08757 springer_journals_10_1007_s00268_018_4551_8 |
| PublicationCentury | 2000 |
| PublicationDate | 20180500 May 2018 2018-05-00 20180501 |
| PublicationDateYYYYMMDD | 2018-05-01 |
| PublicationDate_xml | – month: 5 year: 2018 text: 20180500 |
| PublicationDecade | 2010 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: United States – name: Hoboken |
| PublicationSubtitle | Official Journal of the International Society of Surgery/Société Internationale de Chirurgie |
| PublicationTitle | World journal of surgery |
| PublicationTitleAbbrev | World J Surg |
| PublicationTitleAlternate | World J Surg |
| PublicationYear | 2018 |
| Publisher | Springer International Publishing John Wiley & Sons, Inc |
| Publisher_xml | – name: Springer International Publishing – name: John Wiley & Sons, Inc |
| References | Bano, Hodgson (CR7) 2016; 205 Moura, Cavaco, Leite (CR14) 2015; 22 Taccaliti (CR15) 2011; 12 Takahashi (CR8) 1994; 4 Ball (CR2) 2000 Moura (CR18) 2011; 96 Leboulleux (CR3) 2004; 61 Wells, Santoro (CR13) 2009; 15 Louhibi (CR12) 2014; 61 Krampitz, Norton (CR9) 2014; 120 Fernández-Medarde, Santos (CR16) 2011; 2 Boichard (CR17) 2012; 97 Wells (CR1) 2015; 25 (CR10) 2009; 19 Reagh (CR19) 2017; 41 Eng (CR5) 1996; 276 Learoyd (CR6) 1997; 132 Baumgartner-Parzer (CR11) 2005; 90 Turchini (CR20) 2017; 25 Yamada (CR21) 2016; 107 Wells (CR4) 2013; 98 2015; 25 2017; 41 2004; 61 2011; 2 2000 2013; 98 2017; 25 2005; 90 2016; 107 1997; 132 2015; 22 2011; 96 1996; 276 2016; 205 2011; 12 2009; 19 2014; 61 2014; 120 1994; 4 2009; 15 2012; 97 e_1_2_11_20_2 e_1_2_11_13_2 e_1_2_11_12_2 e_1_2_11_8_2 e_1_2_11_11_2 e_1_2_11_22_2 e_1_2_11_7_2 e_1_2_11_10_2 e_1_2_11_21_2 e_1_2_11_6_2 e_1_2_11_17_2 e_1_2_11_5_2 e_1_2_11_16_2 e_1_2_11_4_2 e_1_2_11_15_2 e_1_2_11_14_2 e_1_2_11_2_2 Ball DW (e_1_2_11_3_2) 2000 e_1_2_11_19_2 e_1_2_11_18_2 Takahashi M (e_1_2_11_9_2) 1994; 4 22865907 - J Clin Endocrinol Metab. 2012 Oct;97(10):E2031-5 19469690 - Thyroid. 2009 Jun;19(6):565-612 26862952 - Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):475-480 9301617 - Arch Surg. 1997 Sep;132(9):1022-5 15355445 - Clin Endocrinol (Oxf). 2004 Sep;61(3):299-310 25810047 - Thyroid. 2015 Jun;25(6):567-610 23744408 - J Clin Endocrinol Metab. 2013 Aug;98(8):3149-64 8918855 - JAMA. 1996 Nov 20;276(19):1575-9 27116474 - Cancer Sci. 2016 Jul;107(7):936-43 27635947 - Am J Surg Pathol. 2017 Jan;41(1):75-81 27075347 - Recent Results Cancer Res. 2016;205:29-44 16118333 - J Clin Endocrinol Metab. 2005 Nov;90(11):6232-6 21779504 - Genes Cancer. 2011 Mar;2(3):344-58 21325462 - J Clin Endocrinol Metab. 2011 May;96(5):E863-8 24794695 - Endocrinol Nutr. 2014 Oct;61(8):398-403 26285815 - Endocr Relat Cancer. 2015 Oct;22(5):R235-52 22654561 - Curr Genomics. 2011 Dec;12(8):618-25 19934298 - Clin Cancer Res. 2009 Dec 1;15(23):7119-23 21566893 - Int J Oncol. 1994 Jan;4(1):81-4 24699901 - Cancer. 2014 Jul 1;120(13):1920-31 |
| References_xml | – volume: 120 start-page: 1920 issue: 13 year: 2014 end-page: 1931 ident: CR9 article-title: RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma publication-title: Cancer doi: 10.1002/cncr.28661 – volume: 25 start-page: 475 issue: 7 year: 2017 end-page: 480 ident: CR20 article-title: NRASQ61R mutation-specific immunohistochemistry is highly specific for either NRASQ61R or KRASQ61R mutation in colorectal carcinoma publication-title: Appl Immunohistochem Mol Morphol doi: 10.1097/PAI.0000000000000333 – volume: 97 start-page: E2031 issue: 10 year: 2012 end-page: E2035 ident: CR17 article-title: Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-2092 – volume: 90 start-page: 6232 issue: 11 year: 2005 end-page: 6236 ident: CR11 article-title: Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2005-1278 – volume: 19 start-page: 565 issue: 6 year: 2009 end-page: 612 ident: CR10 article-title: Medullary thyroid cancer: management guidelines of the American Thyroid Association publication-title: Thyroid doi: 10.1089/thy.2008.0403 – volume: 61 start-page: 299 issue: 3 year: 2004 end-page: 310 ident: CR3 article-title: Medullary thyroid carcinoma publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2004.02037.x – volume: 276 start-page: 1575 issue: 19 year: 1996 end-page: 1579 ident: CR5 article-title: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET Mutation Consortium analysis publication-title: JAMA doi: 10.1001/jama.1996.03540190047028 – volume: 61 start-page: 398 issue: 8 year: 2014 end-page: 403 ident: CR12 article-title: Demographic, clinical, and genetic characteristics of patients with medullary thyroid cancer in the past 16 years in Castilla-La Mancha publication-title: Endocrinol Nutr doi: 10.1016/j.endonu.2014.02.006 – volume: 25 start-page: 567 issue: 6 year: 2015 end-page: 610 ident: CR1 article-title: Revised american thyroid association guidelines for the management of medullary thyroid carcinoma publication-title: Thyroid doi: 10.1089/thy.2014.0335 – volume: 98 start-page: 3149 issue: 8 year: 2013 end-page: 3164 ident: CR4 article-title: Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2013-1204 – volume: 4 start-page: 81 issue: 1 year: 1994 end-page: 84 ident: CR8 article-title: Ret protooncogene and human-diseases—review publication-title: Int J Oncol – volume: 22 start-page: R235 issue: 5 year: 2015 end-page: R252 ident: CR14 article-title: RAS proto-oncogene in medullary thyroid carcinoma publication-title: Endocr Relat Cancer doi: 10.1530/ERC-15-0070 – volume: 15 start-page: 7119 issue: 23 year: 2009 end-page: 7123 ident: CR13 article-title: Targeting the RET pathway in thyroid cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-2742 – volume: 107 start-page: 936 issue: 7 year: 2016 end-page: 943 ident: CR21 article-title: Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer publication-title: Cancer Sci doi: 10.1111/cas.12959 – volume: 132 start-page: 1022 issue: 9 year: 1997 end-page: 1025 ident: CR6 article-title: Genetic testing for familial cancer: consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2 publication-title: Arch Surg doi: 10.1001/archsurg.1997.01430330088015 – volume: 12 start-page: 618 issue: 8 year: 2011 end-page: 625 ident: CR15 article-title: Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers publication-title: Curr Genom doi: 10.2174/138920211798120835 – volume: 205 start-page: 29 year: 2016 end-page: 44 ident: CR7 article-title: Diagnosis and management of hereditary thyroid cancer publication-title: Recent Results Cancer Res doi: 10.1007/978-3-319-29998-3_3 – volume: 96 start-page: E863 issue: 5 year: 2011 end-page: E868 ident: CR18 article-title: High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2010-1921 – start-page: 365 year: 2000 end-page: 381 ident: CR2 publication-title: Medullary thyroid carcinoma, in thyroid cancer – volume: 41 start-page: 75 issue: 1 year: 2017 end-page: 81 ident: CR19 article-title: NRASQ61R mutation-specific Immunohistochemistry Also Identifies the HRASQ61R mutation in medullary thyroid cancer and may have a role in triaging genetic testing for MEN2 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000000740 – volume: 2 start-page: 344 issue: 3 year: 2011 end-page: 358 ident: CR16 article-title: Ras in cancer and developmental diseases publication-title: Genes Cancer doi: 10.1177/1947601911411084 – volume: 61 start-page: 299 issue: 3 year: 2004 end-page: 310 article-title: Medullary thyroid carcinoma publication-title: Clin Endocrinol (Oxf) – volume: 132 start-page: 1022 issue: 9 year: 1997 end-page: 1025 article-title: Genetic testing for familial cancer: consequences of RET proto‐oncogene mutation analysis in multiple endocrine neoplasia, type 2 publication-title: Arch Surg – volume: 2 start-page: 344 issue: 3 year: 2011 end-page: 358 article-title: Ras in cancer and developmental diseases publication-title: Genes Cancer – volume: 120 start-page: 1920 issue: 13 year: 2014 end-page: 1931 article-title: RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma publication-title: Cancer – volume: 90 start-page: 6232 issue: 11 year: 2005 end-page: 6236 article-title: Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? publication-title: J Clin Endocrinol Metab – volume: 22 start-page: R235 issue: 5 year: 2015 end-page: R252 article-title: RAS proto‐oncogene in medullary thyroid carcinoma publication-title: Endocr Relat Cancer – volume: 25 start-page: 567 issue: 6 year: 2015 end-page: 610 article-title: Revised american thyroid association guidelines for the management of medullary thyroid carcinoma publication-title: Thyroid – volume: 97 start-page: E2031 issue: 10 year: 2012 end-page: E2035 article-title: Somatic RAS mutations occur in a large proportion of sporadic RET‐negative medullary thyroid carcinomas and extend to a previously unidentified exon publication-title: J Clin Endocrinol Metab – volume: 12 start-page: 618 issue: 8 year: 2011 end-page: 625 article-title: Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers publication-title: Curr Genom – volume: 19 start-page: 565 issue: 6 year: 2009 end-page: 612 article-title: Medullary thyroid cancer: management guidelines of the American Thyroid Association publication-title: Thyroid – volume: 98 start-page: 3149 issue: 8 year: 2013 end-page: 3164 article-title: Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update publication-title: J Clin Endocrinol Metab – volume: 61 start-page: 398 issue: 8 year: 2014 end-page: 403 article-title: Demographic, clinical, and genetic characteristics of patients with medullary thyroid cancer in the past 16 years in Castilla‐La Mancha publication-title: Endocrinol Nutr – start-page: 365 year: 2000 end-page: 381 – volume: 25 start-page: 475 issue: 7 year: 2017 end-page: 480 article-title: NRASQ61R mutation‐specific immunohistochemistry is highly specific for either NRASQ61R or KRASQ61R mutation in colorectal carcinoma publication-title: Appl Immunohistochem Mol Morphol – volume: 4 start-page: 81 issue: 1 year: 1994 end-page: 84 article-title: Ret protooncogene and human‐diseasesߝreview publication-title: Int J Oncol – volume: 15 start-page: 7119 issue: 23 year: 2009 end-page: 7123 article-title: Targeting the RET pathway in thyroid cancer publication-title: Clin Cancer Res – volume: 96 start-page: E863 issue: 5 year: 2011 end-page: E868 article-title: High prevalence of RAS mutations in RET‐negative sporadic medullary thyroid carcinomas publication-title: J Clin Endocrinol Metab – volume: 205 start-page: 29 year: 2016 end-page: 44 article-title: Diagnosis and management of hereditary thyroid cancer publication-title: Recent Results Cancer Res – volume: 276 start-page: 1575 issue: 19 year: 1996 end-page: 1579 article-title: The relationship between specific RET proto‐oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET Mutation Consortium analysis publication-title: JAMA – volume: 41 start-page: 75 issue: 1 year: 2017 end-page: 81 article-title: NRASQ61R mutation‐specific Immunohistochemistry Also Identifies the HRASQ61R mutation in medullary thyroid cancer and may have a role in triaging genetic testing for MEN2 publication-title: Am J Surg Pathol – volume: 107 start-page: 936 issue: 7 year: 2016 end-page: 943 article-title: Utility of KRAS mutation detection using circulating cell‐free DNA from patients with colorectal cancer publication-title: Cancer Sci – ident: e_1_2_11_4_2 doi: 10.1111/j.1365‐2265.2004.02037.x – ident: e_1_2_11_7_2 doi: 10.1001/archsurg.1997.01430330088015 – ident: e_1_2_11_21_2 doi: 10.1097/PAI.0000000000000333 – ident: e_1_2_11_11_2 doi: 10.1089/thy.2008.0403 – ident: e_1_2_11_16_2 doi: 10.2174/138920211798120835 – ident: e_1_2_11_18_2 doi: 10.1210/jc.2012‐2092 – ident: e_1_2_11_6_2 doi: 10.1001/jama.1996.03540190047028 – ident: e_1_2_11_22_2 doi: 10.1111/cas.12959 – ident: e_1_2_11_8_2 doi: 10.1007/978‐3‐319‐29998‐3_3 – ident: e_1_2_11_5_2 doi: 10.1210/jc.2013‐1204 – ident: e_1_2_11_12_2 doi: 10.1210/jc.2005‐1278 – ident: e_1_2_11_13_2 doi: 10.1016/j.endonu.2014.02.006 – ident: e_1_2_11_20_2 doi: 10.1097/PAS.0000000000000740 – start-page: 365 volume-title: Medullary thyroid carcinoma, in thyroid cancer year: 2000 ident: e_1_2_11_3_2 – ident: e_1_2_11_19_2 doi: 10.1210/jc.2010‐1921 – ident: e_1_2_11_14_2 doi: 10.1158/1078‐0432.CCR‐08‐2742 – ident: e_1_2_11_10_2 doi: 10.1002/cncr.28661 – volume: 4 start-page: 81 issue: 1 year: 1994 ident: e_1_2_11_9_2 article-title: Ret protooncogene and human‐diseasesߝreview publication-title: Int J Oncol – ident: e_1_2_11_15_2 doi: 10.1530/ERC‐15‐0070 – ident: e_1_2_11_17_2 doi: 10.1177/1947601911411084 – ident: e_1_2_11_2_2 doi: 10.1089/thy.2014.0335 – reference: 26862952 - Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):475-480 – reference: 22654561 - Curr Genomics. 2011 Dec;12(8):618-25 – reference: 21779504 - Genes Cancer. 2011 Mar;2(3):344-58 – reference: 27116474 - Cancer Sci. 2016 Jul;107(7):936-43 – reference: 19469690 - Thyroid. 2009 Jun;19(6):565-612 – reference: 26285815 - Endocr Relat Cancer. 2015 Oct;22(5):R235-52 – reference: 9301617 - Arch Surg. 1997 Sep;132(9):1022-5 – reference: 21325462 - J Clin Endocrinol Metab. 2011 May;96(5):E863-8 – reference: 19934298 - Clin Cancer Res. 2009 Dec 1;15(23):7119-23 – reference: 24699901 - Cancer. 2014 Jul 1;120(13):1920-31 – reference: 15355445 - Clin Endocrinol (Oxf). 2004 Sep;61(3):299-310 – reference: 8918855 - JAMA. 1996 Nov 20;276(19):1575-9 – reference: 16118333 - J Clin Endocrinol Metab. 2005 Nov;90(11):6232-6 – reference: 22865907 - J Clin Endocrinol Metab. 2012 Oct;97(10):E2031-5 – reference: 23744408 - J Clin Endocrinol Metab. 2013 Aug;98(8):3149-64 – reference: 25810047 - Thyroid. 2015 Jun;25(6):567-610 – reference: 21566893 - Int J Oncol. 1994 Jan;4(1):81-4 – reference: 24794695 - Endocrinol Nutr. 2014 Oct;61(8):398-403 – reference: 27635947 - Am J Surg Pathol. 2017 Jan;41(1):75-81 – reference: 27075347 - Recent Results Cancer Res. 2016;205:29-44 |
| SSID | ssj0017606 |
| Score | 2.3055155 |
| Snippet | Introduction
Medullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer.... Medullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer. Familial cases of... IntroductionMedullary thyroid cancer (MTC) is a rare tumour of neuroendocrine origin with a more aggressive profile than differentiated thyroid cancer.... |
| SourceID | proquest pubmed crossref wiley springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1432 |
| SubjectTerms | Abdominal Surgery Age Calcitonin Cancer Cardiac Surgery Females General Surgery Genetic screening Identification methods Immunohistochemistry Males Medicine Medicine & Public Health Metastases Multiple endocrine neoplasia Multivariate analysis Mutation Neuroendocrine tumors Original Scientific Report Patients Surgery Survival Survival analysis Thoracic Surgery Thyroid Thyroid cancer Thyroid carcinoma Tumors Vascular Surgery |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxwxEB-qleKLttrqqi0p-NQSyGWzm41venq0pUrxrPq2JNmEHuiu3Idw_4F_tkn2w0qLpe7TwibZYTLJzPBL5gewK62wVHn2MmoIZqYnsOIywTERLh-xjCUBaD__zk9OsstL8aO5xz1pT7u3kGTYqbvLbj5d8AevMsycm8fZArx03i7zq_F0eN5BBzwlDUDJsAte4hbK_NsQj53RHxHmb-jo49g1OJ_B6rPEfg0rTayJ9mvjeAMvTLkGr44bNH0d7tyry0DleI7Ofs3H1ahAfU8tVFbXcg8NZ24XufX9m7olSJYFOuqqg6PKouNZjeTjQGNvRxp99fdNqlDFWLdccmhUokMzDYe-QjdPrS6dFOiwhofews_B0Vn_C26YGbBmlHKsdepTHcaNNAUxhCslE6WLjFnjOWNSTlzGninJtYuAUp16k0iZcn4ysTKN43ewWFal2QREU2WE7cUFjTkzQigmE-u2b0OI4kWPRkDaKcp1U7bcs2dc5V3B5aDh3Gk49xrOswg-dV1u6podTzXeaec9b5bvJHBzej62Ho_gY_fZ6cyjKbI01axu4x6RkAg2anvp_kaFUw7jSQSfW6N4GPwJUWiwsX8LnV98Gx4MAhnB1n_9YhuWqTfFcGJzBxan45l5D0v6djqajD-EhXQPTWYUww priority: 102 providerName: Springer Nature |
| Title | Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease |
| URI | https://link.springer.com/article/10.1007/s00268-018-4551-8 https://onlinelibrary.wiley.com/doi/abs/10.1007%2Fs00268-018-4551-8 https://www.ncbi.nlm.nih.gov/pubmed/29484475 https://www.proquest.com/docview/2008197217 https://www.proquest.com/docview/2008888950 |
| Volume | 42 |
| WOSCitedRecordID | wos000429808200029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 1432-2323 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0017606 issn: 0364-2313 databaseCode: 7X7 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central Database Suite (ProQuest) customDbUrl: eissn: 1432-2323 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0017606 issn: 0364-2313 databaseCode: BENPR dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-2323 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017606 issn: 0364-2313 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RLQcuPMSjgbYyEieQhddx7IQL6mNXgOiq6payt8h2bLESJGUflfoP-NnYjpNSIS0HcogUxU4cz9gz48-ZD-CVtIWlyrOXUUMwM8MCKyEznJLCxSOWsSwA7RefxWSSz2bFaVxwW8Ztld2cGCbqqtF-jfwtDcbLxSvi_eVP7FmjPLoaKTS2YNtnKmMD2D4cTU7PehxBcBLRSoadJ5N2uCYJaUQp9xu5csyc24Dz25bpL3fzD6j0tiMbLNH4wf9-w0O4H31QdNAqzSO4Y-rH8OvEGR2nE4trdP7tetHMK3TkeYbq5od8h6ZrN6Vc-UoxiQmSdYVGfapw1Fh0sm5hfRw47e1co4_-55MmpDTWHbEcmtfo2KzCDrBQzfOsy8qVPm6xoifwZTw6P_qAI00D1oxSgbXmPu5hwkhTEUOEUjJTusqZNZ5AhgviwvdcSaGdO8Q19_rBmXJGM7OSp-lTGNRNbXYAUa5MYYdpRVPBTFEoJjPr5nJDiBLVkCZAOhGVOuYw91Qa38s--3KQaumkWnqplnkCr_sql20Cj02FdzvBlXEsL8sbqSXwsr_t-sxDK7I2zbot444iIwk8a_WlfxstXOcwkSXwplOgm4dvaAoNOvbvRpdfP00Px4GZ4Pnm9r-Ae9Tre9ivuQuD1WJt9uCuvlrNl4t92BIzEc75fhxH7upsevEbLLYgQQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD6aBhK8cBG3jgFGgheQhes6cYKEEKyrVtZWSC3Qt8x2HFGJJaWXof4Dfg2_kWPnMiak8rQH8ho7sZ3P5-Jzcj6AZyqLM64dexm3jArbjqmWKqAdFqM_kgkR-ED754EcjaLpNP64A7_qf2FcWmUtE72gTgvjzshfca-80F-Rb-ffqWONctHVmkKjhMWx3fxAl235pt_F7_uc897h5OCIVqwC1AjOJTUmdGa6kFbZlFkmtVaBNmkkMuv4TkLJ0NuMtJIGtXdoQjedUGiU8UGmQncAiiL_Cspx6VLI5LRx8NoyZFVsVFC0mzp1FJX5oqU8dGljERVopNDooh78y7j9IzB70Wz2eq93839bsVtwo7KwybtyS9yGHZvfgZ9DVKmI-MWGTL5uFsUsJQeORSkvTtVrMl6jwDxznaoSLUTlKTlsCqGTIiPDdZm0QMdz6_MYSd_9WlP4gs2mps0js5x07crnt_lujkVepdi6W0bC7sKnS5n8PdjNi9w-AMJDbeOs3Ul5Rwobx1qoIENNZRnTMm3zFrAaEompKrQ7opBvSVNb2qMoQRQlDkVJ1IIXTZd5WZ5kW-P9GihJJamWyTlKWvC0uY1r5gJHKrfFumyDVxywFtwv8dm8jce4OEIGLXhZA_b84VuGwj2m_z3o5MuH8fue513Y2z7-J3DtaDIcJIP-6PghXOdur_nM1H3YXS3W9hFcNWer2XLx2O9aAieXDfrfnTR5hg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD6aOoR44SJuhQFGgheQNdd14gQJIba2omyrKjrY3oLtOKISJKWXof4DfhO_jmPnMiak8rQH8ho7sZ3P5-Jzcj6AZyqLM64dexm3jArbiamWKqBdFqM_kgkR-ED7p0M5GkWnp_F4C37V_8K4tMpaJnpBnRbGnZHvcq-80F-Ru1mVFjHuDd7MvlPHIOUirTWdRgmRA7v-ge7b4vWwh9_6OeeD_vH-O1oxDFAjOJfUmNCZ7EJaZVNmmdRaBdqkkcis4z4JJUPPM9JKGtTkoQnd1EKhUd4HmQrdYSiK_22JRkbQgu29_mj8oYlhyJBVkVJB0Yrq1jFV5kuY8tAlkUVUoMlCo4ta8S9T948w7UUj2mvBwY3_ef1uwvXK9iZvy81yC7Zsfht-HqGyxb0wX5PjL-t5MU3JvuNXyotv6hWZrFCUnrlOVfEWovKU9JsS6aTIyNGqTGegk5n1GY5k6H66KXwpZ1MT6pFpTnp26TPffDfHL69SbN0rY2R34OOlTP4utPIit_eB8FDbOOt0U96VwsaxFirIUIdZxrRMO7wNrIZHYqra7Y5C5GvSVJ32iEoQUYlDVBK14UXTZVYWLtnUeKcGTVLJsEVyjpg2PG1u45q5kJLKbbEq2-AVB6wN90qsNm_jMS6OkEEbXtbgPX_4hqFwj-9_Dzo5eT_ZG3hGhgebx_8EriLWk8Ph6OAhXONu2_mU1R1oLecr-wiumLPldDF_XG1hAp8vG_W_AXhvg6Y |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Medullary+Thyroid+Carcinoma%3A+Survival+Analysis+and+Evaluation+of+Mutation%E2%80%90Specific+Immunohistochemistry+in+Detection+of+Sporadic+Disease&rft.jtitle=World+journal+of+surgery&rft.au=Jayakody%2C+S.&rft.au=Reagh%2C+J.&rft.au=Bullock%2C+M.&rft.au=Aniss%2C+A.&rft.date=2018-05-01&rft.issn=0364-2313&rft.eissn=1432-2323&rft.volume=42&rft.issue=5&rft.spage=1432&rft.epage=1439&rft_id=info:doi/10.1007%2Fs00268-018-4551-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00268_018_4551_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0364-2313&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0364-2313&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0364-2313&client=summon |